Lifeward and MYOLYN Expand Partnership to Enhance Patient Access to MyoCycle FES Cycling Therapy System for Home Use

Rhea-AI Summary

Lifeward (Nasdaq: LFWD) and MYOLYN have expanded their exclusive partnership to enhance patient access to the MyoCycle FES Cycling Therapy System for home use. The expanded agreement allows Lifeward to manage referrals and sales of MyoCycle Home products for patients transitioning from clinical to home use.

MyoCycle is a stationary exercise bike with integrated electrical stimulation designed for individuals with muscle weakness or paralysis due to conditions like spinal cord injury, multiple sclerosis, and stroke. Previously, Lifeward managed hospital and clinic-based sales of MyoCycle Pro nationwide, as well as home use sales for VA and Workers' Compensation beneficiaries.

Under the new arrangement, MYOLYN will continue directly servicing patients already discharged from therapy. Lifeward has established the necessary case management infrastructure to support anticipated growth in the MyoCycle product line, leveraging shared resources between MyoCycle and ReWalk Exoskeleton.

Positive

• Expanded market reach through new home-use sales channel
• Leverages existing case management infrastructure
• Enhanced revenue potential from clinical-to-home patient transitions

Negative

• Shared market approach may limit full revenue potential
• MYOLYN retains direct sales rights for discharged patients

Insights

Healthcare Business Strategy Expert

This expanded partnership represents a strategic market extension for Lifeward into the home-use rehabilitation device segment. By securing management rights for MyoCycle Home product referrals and sales for patients transitioning from clinical settings, Lifeward establishes a important continuum-of-care revenue model with significant growth potential.

The agreement creates a complete patient journey pipeline where Lifeward can now monetize the entire treatment pathway – from clinic-based therapy (which they already managed) through to home continuation therapy. This continuity model typically produces higher patient retention rates and extended revenue streams per patient.

Particularly promising is the mention of existing infrastructure compatibility, with Lifeward stating they've "already built the significant case management infrastructure necessary to support the anticipated growth." This suggests minimal additional overhead costs while leveraging operational synergies between their ReWalk Exoskeleton line and the MyoCycle products.

For a company with Lifeward's modest market capitalization ($17.75 million), securing expanded distribution rights into the growing home rehabilitation market represents a meaningful business development. The home medical equipment market has seen accelerated growth following the pandemic as patients increasingly prefer at-home treatment options, making this an opportune market expansion.

Medical Device Industry Analyst

This expanded partnership strategically positions Lifeward to capitalize on the important clinical-to-home transition phase in rehabilitation therapy. The FES cycling market addresses multiple large patient populations – including those with spinal cord injuries, multiple sclerosis, and stroke recovery – creating a substantial addressable market.

What makes this arrangement particularly valuable is the referral-based sales model. Clinician referrals carry significant weight in medical device adoption and typically result in higher conversion rates and reduced customer acquisition costs compared to direct-to-consumer approaches. By managing the therapist-referred segment while MYOLYN handles direct consumer sales, Lifeward secures the higher-probability conversion channel.

The agreement's structure also creates natural patient segmentation that maximizes operational efficiency. Lifeward focuses on institutional sales and therapy-referred home users (leveraging their existing reimbursement expertise with VA and Workers' Compensation), while MYOLYN handles patients already discharged from therapy seeking direct purchases.

For investors, this expansion represents measured growth into an adjacent market without significant capital requirements, as confirmed by management's statement about existing infrastructure compatibility. The agreement should improve revenue predictability by capturing patients through their entire rehabilitation journey rather than losing them during the clinical-to-home transition.

New Agreement Expands Distribution Rights to Lifeward to Include Referral Sales for Home Use Applications

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel and GAINESVILLE, Fla., March 05, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, and MYOLYN, Inc. (“MYOLYN”) a leading medical technology company specializing in functional electrical stimulation (“FES”) therapy, jointly announced today that the companies are expanding their exclusive contract to increase patient access to the MyoCycle FES Cycling Therapy System (“MyoCycle”) for home use through the Lifeward organization.

MYOLYN is best known for its innovative, affordable, and easy-to-use MyoCycle, a stationary exercise bike with integrated electrical stimulation to the user’s muscles to provide therapeutic exercise for individuals experiencing muscle weakness or paralysis caused by disorders like spinal cord injury, multiple sclerosis, and stroke. Based on the new contract, Lifeward will add management of referrals and sales of the MyoCycle Home product for patients that are transitioning from clinical use to home use. This expanded contract builds upon the existing distribution agreement between the two companies, under which Lifeward has been managing all hospital and clinic-based sales of the MyoCycle Pro product nationwide, as well as home use sales for individuals with VA and Workers’ Compensation benefits. The new agreement will expand the partnership to include sales to individuals referred by their therapist for home use of the MyoCycle Home. MYOLYN will continue to directly service patients who are already discharged from therapy and want to maximize their health and recovery with a home FES cycling program.

“We are so pleased to grow and strengthen our partnership with MYOLYN,” said Larry Jasinski, CEO of Lifeward. “We see great opportunity to better serve the patients who have completed their therapy in the clinic and want to continue their rehabilitation at home. This agreement will significantly expand Lifeward’s ability to continue to serve these patients, and Lifeward has already built the significant case management infrastructure necessary to support the anticipated growth in the MyoCycle product line, due to the shared nature of these internal resources between the MyoCycle and the ReWalk Exoskeleton.”

“Our mission has always been to make our products accessible to those who need them,” said Alan Hamlet, Co-Founder and CEO of MYOLYN. “By expanding our partnership with Lifeward, we can help more patients receive the care they need and assist them in the transition from clinical to home use.”

For more information, please visit GoLifeward.com and www.myolyn.com.

About Lifeward

Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity System, the ReStore Exo-Suit, and the MyoCycle FES System. Founded in 2001, Lifeward has operations in the United States, Israel, and Germany.

Lifeward^®, ReWalk^®, ReStore^®, and Alter G^® are registered trademarks of Lifeward Ltd. and/or its affiliates.

About MYOLYN

MYOLYN is an innovative medical technology company dedicated to improving health and human performance by empowering people to move. The company designs, manufactures, and distributes devices that leverage electrical stimulation to improve muscle performance. The company’s flagship product, the MyoCycle FES Cycling Therapy System, enables patients with paralysis to perform therapeutic cycling exercise, maximizing recovery, preventing secondary health consequences, and improving quality of life.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: the Company’s ability to realize the anticipated benefits of the acquisition of AlterG, including the possibility that the expected benefits of the acquisition will not be realized within the expected time period or at all; the effect of the AlterG acquisition on the ability of the Company to retain customers and key personnel and to maintain relationships with suppliers, distributors and other key business relations; potential litigation in connection with the AlterG acquisition; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2023 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Lifeward Media Relations:
Kathleen O’Donnell
Vice President, Marketing & New Business Development
Lifeward Ltd.
E: media@golifeward.com

Lifeward Investor Contact:
Mike Lawless
Chief Financial Officer
Lifeward Ltd.
E: ir@golifeward.com

FAQ

What is the expanded partnership between Lifeward (LFWD) and MYOLYN announced in March 2025?

Lifeward will now manage referrals and sales of MyoCycle Home products for patients transitioning from clinical to home use, expanding beyond their existing hospital and clinic-based sales.

How does the MyoCycle FES Cycling Therapy System work?

MyoCycle is a stationary exercise bike with integrated electrical stimulation that provides therapeutic exercise for people with muscle weakness or paralysis from conditions like spinal cord injury, MS, and stroke.

What markets does Lifeward (LFWD) currently serve for MyoCycle sales?

Lifeward manages hospital and clinic-based sales nationwide, home use sales for VA and Workers' Compensation benefits, and now referral sales for home use transitions.

Who will handle MyoCycle sales for discharged patients under the new LFWD agreement?

MYOLYN will continue to directly service patients who are already discharged from therapy and want to use MyoCycle for home FES cycling programs.